<DOC>
	<DOCNO>NCT02750397</DOCNO>
	<brief_summary>HIV-infected ( HIV+ ) individual agree accept receive solid organ transplant HIV+ decease donor follow determine safety efficacy practice . HIV+ individual receive solid organ transplant HIV-uninfected donor also follow .</brief_summary>
	<brief_title>HIV-to-HIV Transplant MGH</brief_title>
	<detailed_description>This observational study design evaluate safety outcome solid organ transplantation HIV+ recipient HIV+ decease donor . This study evaluate overall survival graft survival compare transplantation HIV- organ . In addition study assess potential complication organ transplant use HIV+ decease donor - include limited - HIV superinfection , incidence severity graft rejection , recurrence HIV-associated nephropathy , incidence bacterial infection , opportunistic infection .</detailed_description>
	<criteria>1 . Participant able understand provide inform consent 2 . Participant meet standard list criterion transplant . 3 . Documented HIV infection ( licensed ELISA confirmation Western Blot , positive HIV ab IFA , document history detectable HIV1 RNA ) . 4 . Participant ≥ 18 year old . 5 . Opportunistic Complications : None previous history protocol allow opportunistic infection neoplasms appropriate acute maintenance therapy evidence active disease . 6 . Participant CD4+ Tcell count &gt; /= 200/μL prior renal transplant liver transplant &gt; /= 100/μL within 16 week prior transplant history opportunistic infection ( OI ) ; ≥200 μL history OI present . 7 . Participant HIV1 RNA &lt; 50 copies/mL ( FDAapproved assay perform CLIAapproved laboratory ) , 26 week prior transplant . Nonconsecutive viral `` blip '' 50400 copy RNA/mL allow . 8 . Antiretroviral therapy : To avoid drug interaction , ritonavir cobicistatcontaining regimen recommend , unless opinion HIV/Transplant Infectious Disease team alternative regimen expect control HIV replication . 9 . Participant willing use PCP , herpes virus fungal prophylaxis indicate . 1 . Participant concomitant condition , judgment investigator , would preclude transplantation immunosuppression . 2 . Opportunistic Complication History : Any history progressive multifocal leukoencephalopathy ( PML ) , chronic intestinal cryptosporidiosis &gt; 1 month duration , primary CNS lymphoma . 3 . Participant history neoplasm except follow : resolve kaposi 's sarcoma , situ anogenital carcinoma , adequatelytreated basal squamous cell carcinoma skin , solid tumor ( except primary CNS lymphoma ) treat curative therapy disease free 5 year . History renal cell carcinoma require disease free state 2 year . History leukemia diseasefree duration per site policy . 4 . Participant pregnant breastfeeding . Note : Participants become pregnant posttransplant continue follow study manage per clinical practice . Women become pregnant breastfeed .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>HIV</keyword>
	<keyword>Kidney Transplant</keyword>
	<keyword>Liver Transplant</keyword>
	<keyword>Transplant</keyword>
</DOC>